Nature Communications (Mar 2020)
Low rates of mutation in clinical grade human pluripotent stem cells under different culture conditions
- Oliver Thompson,
- Ferdinand von Meyenn,
- Zoe Hewitt,
- John Alexander,
- Andrew Wood,
- Richard Weightman,
- Sian Gregory,
- Felix Krueger,
- Simon Andrews,
- Ivana Barbaric,
- Paul J. Gokhale,
- Harry D. Moore,
- Wolf Reik,
- Marta Milo,
- Serena Nik-Zainal,
- Kosuke Yusa,
- Peter W. Andrews
Affiliations
- Oliver Thompson
- The Centre for Stem Cell Biology, Department of Biomedical Science, University of Sheffield, Western Bank
- Ferdinand von Meyenn
- Epigenetics Programme, Babraham Institute
- Zoe Hewitt
- The Centre for Stem Cell Biology, Department of Biomedical Science, University of Sheffield, Western Bank
- John Alexander
- The Centre for Stem Cell Biology, Department of Biomedical Science, University of Sheffield, Western Bank
- Andrew Wood
- The Centre for Stem Cell Biology, Department of Biomedical Science, University of Sheffield, Western Bank
- Richard Weightman
- The Centre for Stem Cell Biology, Department of Biomedical Science, University of Sheffield, Western Bank
- Sian Gregory
- The Centre for Stem Cell Biology, Department of Biomedical Science, University of Sheffield, Western Bank
- Felix Krueger
- Bioinformatics Group, Babraham Institute
- Simon Andrews
- Bioinformatics Group, Babraham Institute
- Ivana Barbaric
- The Centre for Stem Cell Biology, Department of Biomedical Science, University of Sheffield, Western Bank
- Paul J. Gokhale
- The Centre for Stem Cell Biology, Department of Biomedical Science, University of Sheffield, Western Bank
- Harry D. Moore
- The Centre for Stem Cell Biology, Department of Biomedical Science, University of Sheffield, Western Bank
- Wolf Reik
- Epigenetics Programme, Babraham Institute
- Marta Milo
- The Centre for Stem Cell Biology, Department of Biomedical Science, University of Sheffield, Western Bank
- Serena Nik-Zainal
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton
- Kosuke Yusa
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton
- Peter W. Andrews
- The Centre for Stem Cell Biology, Department of Biomedical Science, University of Sheffield, Western Bank
- DOI
- https://doi.org/10.1038/s41467-020-15271-3
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 14
Abstract
Mutations in human pluripotent stem cells (PSC) and whether any form during culture prior to use in a human clinical context are a concern. Here, the authors use hPSCs derived to cGMP standards and show they have low mutation rates after culture, noting this decreases on culturing in low (5%) oxygen conditions.
